eXoZymes
exozymes.com
Bioprocessing
Industrial Biotechnology
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$12k
7 rounds on record
Latest round
$12k
Convertible Note · Nov 2024 · 23 mo ago
Grants
$3.2M
6 grants · CORDIS
The money's age
Due for its next round
23 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 1, 2025
Won a grant $284k · CORDIS
Nov 14, 2024
Raised a round Convertible Note $12k · SEC Form D
Feb 1, 2024
Won a grant $244k · CORDIS
Aug 8, 2022
Won a grant $250k · CORDIS
Dec 13, 2021
Won a grant $2.1M · CORDIS
Apr 1, 2020
Won a grant $150k · CORDIS
Jul 1, 2019
Won a grant $200k · CORDIS
2019
Founded
Funding rounds
Registers and programsofficial lists and records that name the company
| Legal entity | Invizyne Technologies Inc | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael HeltzenExecutive OfficerSEC Form D
Mohammad HayatExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Accelerate biomanufacturing with Silvia Bio's cell profiling platform and precision media additives. Boost titre and quality in mammalian…
Caladan Bio delivers automated high-throughput benchtop bioreactor systems for fermentation and cell culture teams.
Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at…
Patented ELAREM™ cell culture supplements: Human Platelet Lysate (HPL) xeno-free NEW: Artificial HPL PL BioScience.
Intelligent robotics for cell culture automation. Whelix combines AI agents with lab robotics so your biology runs 24/7 — protocols…
Unlocking Cellular Innovation. The first-choice bioprocessing and scale-up partner for the sustainable bioeconomy.
Overview
Unlocking new medicines: Where chemistry hits its limits, cell-free biology begins. A rare natural product that activates the cell's master metabolic control switch - finally available at scale.
News
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.Estimated manufacturing cost equivalent has fallen
Read more
Report
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern .
Read more
Report
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar
Read more
Report
eXoZymes Completes New Securities Offering to Fund Pipeline
Detailed price information for Exozymes Inc (EXOZ-Q) from The Globe and Mail including charting and trades.
Read more
Report
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
LOS ANGELES, CA/ ACCESS Newswire/ March 25, 2026/ Today, eXoZymes Inc.- a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines- announced the plan to host a webinar on Tuesday, March 31, 2026 a
Read more
Report
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 /Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals ...
Read more
Report
Report
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
Read more
Report
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
eXoZymes Inc. (NASDAQ:EXOZ) "eXoZymes" - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medici ...
Read more
Report
People
Michael Heltzen
Executive Officer
Mohammad Hayat
Executive Officer, Director
Lon Bell
Director
Anthony DiGiandomenico
Director
James Bowie
Director
Christopher Marlett
Director
James Lalonde
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1